H
Hall
Researcher at National Institutes of Health
Publications - 22
Citations - 381
Hall is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Protein–protein interaction & Genome editing. The author has an hindex of 7, co-authored 22 publications receiving 320 citations.
Papers
More filters
Cell Viability Assays -- Assay Guidance Manual
Sittampalam Gs,Grossman A,Brimacombe K,Arkin M,Auld D,Austin C,Baell J,Bejcek B,Caaveiro Jmm,Chung Tdy,Nathan P. Coussens,Dahlin Jl,Devanaryan,Foley Tl,Glicksman M,Hall,Haas Jv,Hoare Srj,Inglese J,Iversen Pw,Kahl Sd,Stephen C. Kales,Kirshner S,Lal-Nag M,Li Z,McGee J,McManus O,Riss T,Saradjian P,Trask Oj,Weidner,Wildey Mj,Xia M,Xu X +33 more
Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies -- Assay Guidance Manual
Sittampalam Gs,Grossman A,Brimacombe K,Arkin M,Auld D,Austin C,Baell J,Bejcek B,Caaveiro Jmm,Chung Tdy,Nathan P. Coussens,Dahlin Jl,Devanaryan,Foley Tl,Glicksman M,Hall,Haas Jv,Hoare Srj,Inglese J,Iversen Pw,Kahl Sd,Stephen C. Kales,Kirshner S,Lal-Nag M,Li Z,McGee J,McManus O,Riss T,Saradjian P,Trask Oj,Weidner,Wildey Mj,Xia M,Xu X +33 more
TL;DR: This chapter contains guidelines to develop therapeutic hypothesis, target and pathway validation, proof of concept criteria and generalized cost analysis at various stages of early drug discovery.
Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats -- Assay Guidance Manual
Sittampalam Gs,Grossman A,Brimacombe K,Arkin M,Auld D,Austin C,Baell J,Bejcek B,Caaveiro Jmm,Chung Tdy,Nathan P. Coussens,Dahlin Jl,Devanaryan,Foley Tl,Glicksman M,Hall,Haas Jv,Hoare Srj,Inglese J,Iversen Pw,Kahl Sd,Stephen C. Kales,Kirshner S,Lal-Nag M,Li Z,McGee J,McManus O,Riss T,Saradjian P,Trask Oj,Weidner,Wildey Mj,Xia M,Xu X +33 more
Posted ContentDOI
Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19
TL;DR: Remdesivir is a nucleotide analog prodrug that perturbs viral replication that was originally evaluated in clinical trials to thwart the Ebola outbreak in 2014 and demonstrated the ability to inhibit coronavirus replication, including SARS-CoV-2.
HTS Assay Validation -- Assay Guidance Manual
Sittampalam Gs,Grossman A,Brimacombe K,Arkin M,Auld D,Austin C,Baell J,Bejcek B,Caaveiro Jmm,Chung Tdy,Nathan P. Coussens,Dahlin Jl,Devanaryan,Foley Tl,Glicksman M,Hall,Haas Jv,Hoare Srj,Inglese J,Iversen Pw,Kahl Sd,Stephen C. Kales,Kirshner S,Lal-Nag M,Li Z,McGee J,McManus O,Riss T,Saradjian P,Trask Oj,Weidner,Wildey Mj,Xia M,Xu X +33 more